## **Amendments to the Claims:**

Please amend claims 1-2, 5-6 and 9-10. Please cancel claims 3-4, 7-8 and 21-23. Following entrance of this amendment, claims 1-2, 5-6 and 9-10 will be pending and under consideration. This listing of claims will replace all prior versions, and listings, of claims in this application.

## **Listing of Claims:**

Claim 1. (Currently amended): A method of preventing and/or treating osteoarthritis in a patient in need thereof comprising orally administering to said patient a pharmaceutical composition comprising between 0.4 and 2.5 mg of salmon calcitonin a therapeutically effective amount of a calcitonin in free or salt form and a delivery agent selected from the group of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoly]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and disodium salts thereof.

Claim 2. (Currently amended): A method of inhibiting resorption and/or normalizing turnover of subchondral bone in a patient <a href="https://hxi.org/harmaceutical-need-thereof">having osteoarthritis or osteoporosis</a>, or in a postmenopausal woman in need thereof comprising <a href="https://orally.com/orally-administering">orally</a> administering to said patient a <a href="https://orally.com/patient-therapeutical-need-therap

Claim 3-4. (Canceled)

Claim 5. (Currently amended): The method according to claim 1, wherein the therapeutically effective amount of a salmon calcitonin is delivered orally in a composition comprising the calcitonin which is conjugated to a polymer molecule.

Claim 6. (Currently amended): The method according to claim 1, wherein the therapeutically effective amount of a calcitonin is delivered with an effective dosage of an oral pharmaceutical composition comprising further comprises calcitonin, at least one pharmaceutically acceptable pH-lowering agent, at least one absorption enhancer, and an enteric coating.

Claim 7-8. (Canceled)

Claim 9. (Currently amended): The method according to claim 4 claim 6, whereas said pharmaceutical composition comprises a delivery agent selected from the group consisting of a disodium salt of 5-CNAC, a disodium salt of SNAD and a disodium salt of SNAC.

Claim 10. (Currently amended): The method according to claim 4 claim 9, whereas said pharmaceutical composition comprises a delivery agent in micronized form.

Claims 11-16. (Canceled)

Claim 17. (Withdrawn): A pharmaceutical composition for use in the treatment or/and prevention of osteoarthritis in a patient in need thereof, comprising a calcitonin together with one or more pharmaceutically acceptable diluents or carriers therefore.

Claim 18. (Withdrawn): A pharmaceutical combination for use in the treatment or/and prevention of osteoarthritis in a patent thereof, comprising:

- a) a first agent which is a calcitonin, and
- b) a co-agent which is a bone resorption inhibitor, bone forming during or pain reducing agent.

Claim 19. (Withdrawn): A pharmaceutical composition comprising between 0.4 and 2.5 mg of a calcitonin.

Claim 20-23. (Canceled)